Nothing said here yet.
to join the conversation.
Galderma Group has delivered a strong share price run over the past year, and the recent flow of product and deal news keeps the story in the headlines.
ZUG, Switzerland, October 23, 2026--Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company’s Injectable…
Investing.com -- Swiss dermatology group Galderma raised its 2026 sales growth guidance on Thursday after third-quarter growth of 26% at constant currency beat analyst expectations, though it kept its core EBITDA margin target at about 26%.
ZUG, Switzerland, October 22, 2026--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026.
ZUG, Switzerland, October 21, 2026--Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Dubai, United Arab Emirates (UAE), from…
ZUG, Switzerland & IRVINE, Calif., October 14, 2026--Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, from…
Investing.com -- Swiss skincare group Galderma said on Wednesday it had agreed to buy ZO Skin Health, a physician-dispensed skincare brand owned by Blackstone, for an enterprise value of $1.5 billion in cash, expanding its dermatological skincare business as…
ZUG, Switzerland, October 13, 2026--Galderma (SIX: GALD) today announced new global research revealing that more than half (56%) of women first put menopause-related skin changes down to general ageing, while only less than a third of women (29%) initially…
ZUG, Switzerland, October 08, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis to be presented at the 2026 Fall Clinical Dermatology…
ZUG, Switzerland, September 30, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained…
ZUG, Switzerland, September 23, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress.
Galderma Group (SWX:GALD) has just raised its full-year 2026 net sales growth guidance to a range of 19% to 21% at constant currency, after reporting 24.6% year-on-year net sales growth in the first half.